Court Says Pfizer's Biosimilar of J & J's Remicade Doesn't Infringe Patent

Pfizer ’s lower-priced version of Johnson& Johnson ’s blockbuster autoimmune disease drug Remicade doesn’t infringe a patent, a federal court ruled, potentially clearing the way for the drug’s sale in October.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news